Thermo Fisher Scientific announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE‑SG100K study, a large population‑scale biobank initiative that will enroll 100,000 participants across Singapore’s diverse population.
The partnership will deploy Thermo Fisher’s Olink® Proximity Extension Assay (PEA) platforms and its Orbitrap Astral mass spectrometry system to generate high‑sensitivity, targeted protein measurements and deep, unbiased discovery proteomics. In addition, Seer’s Proteograph® Product Suite will profile the plasma proteome of 10,000 samples, creating a comprehensive, multi‑omic data set that will support disease research and risk modeling.
This collaboration expands Thermo Fisher’s footprint in the rapidly growing biobank and precision‑medicine market and complements the company’s existing involvement in large‑scale projects such as the UK Biobank Pharma Proteomics Project, Finland’s FinnGen, and the MyCode Community Health Initiative in the United States. By embedding its technologies in the national precision‑medicine program, Thermo Fisher positions itself as a one‑stop shop for proteomics and mass spectrometry services in Asia.
Thermo Fisher’s recent financial performance underscores its capacity to invest in such initiatives. The company reported Q4 2025 revenue of $12.21 billion and adjusted earnings per share of $6.57, both exceeding analyst estimates. For the full year 2025, revenue reached $44.56 billion and adjusted EPS was $22.87, reflecting strong demand across its core segments and effective cost control.
Management highlighted the strategic importance of the partnership. Chairman and CEO Marc N. Casper said, "Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health. By combining our deep scientific expertise with industry‑leading technologies, we are helping national health leaders translate complex biological data into insights that can fundamentally transform human health." Chief Scientific Officer Karen Nelson added, "National biobank initiatives require technologies that deliver both breadth and precision. This complementary strategy sets a new standard for multi‑proteomics analysis and empowers researchers to see true disease biology with speed and at scale." PRECISE’s lead principal investigator John Chambers noted, "By applying this integrated proteomics approach across our national cohort, we gain a dynamic view of disease biology within Singapore's uniquely diverse population. This model strengthens our ability to uncover early molecular signals of disease, understand risk across different global communities and generate insights that can inform the future of population health."
The announcement was met with a modest market reaction, with analysts noting the partnership’s potential to drive future growth and reinforce Thermo Fisher’s leadership in proteomics and mass spectrometry services.
The collaboration is expected to generate significant data‑driven revenue streams and strengthen Thermo Fisher’s position as a comprehensive provider of proteomics solutions, positioning the company for continued growth in the precision‑medicine sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.